PROKIDNEY CORP.(PROK)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

PROKIDNEY CORP. (PROK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PROK at 25.8/100 on a 32-signal composite quality model, placing it at rank #2,652 of 2,962 stocks — the bottom half of the AI-ranked universe. PROK scores in the top quartile across revenue growth (98.4), institutional flow (92.2). Areas of concern include free cash flow (0.2) and revenue scale (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PROKIDNEY CORP. reports quarterly revenue of $150.0K, net income of $-28.4M, free cash flow of $-44.2M. Top institutional holders of PROK by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, MORGAN STANLEY, BlackRock, based on the most recent SEC filings. PROK trades on the Nasdaq exchange and files with the SEC under CIK 1850270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PROK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROKIDNEY CORP. directly from SEC EDGAR.